Elite Pharmaceuticals, Inc.: other noncurrent assets

What this measure means

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Exact concept: us-gaap:OtherAssetsNoncurrent. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2014-03-31 to 2020-03-31. The SEC response was captured on 2026-09-20.

This selected history ends more than two years before capture. Do not treat its final value as a current balance or current annual result. More recent filings may use another accounting tag; inspect the filings before drawing conclusions about the company.

Selected filing history

Related financial histories

• Elite Pharmaceuticals, Inc.: total assets
• Elite Pharmaceuticals, Inc.: total liabilities
• Elite Pharmaceuticals, Inc.: stockholders equity
• Elite Pharmaceuticals, Inc.: cash and cash equivalents
• Elite Pharmaceuticals, Inc.: net income or loss
• Elite Pharmaceuticals, Inc.: operating cash flow
• Elite Pharmaceuticals, Inc.: capital expenditure payments
• Elite Pharmaceuticals, Inc.: revenue
• Elite Pharmaceuticals, Inc.: contract revenue excluding tax
• Elite Pharmaceuticals, Inc.: financing cash flow
• Elite Pharmaceuticals, Inc.: investing cash flow
• Elite Pharmaceuticals, Inc.: retained earnings or deficit
• Elite Pharmaceuticals, Inc.: basic weighted-average shares
• Elite Pharmaceuticals, Inc.: diluted weighted-average shares
• Elite Pharmaceuticals, Inc.: basic earnings per share
• Elite Pharmaceuticals, Inc.: diluted earnings per share
• Elite Pharmaceuticals, Inc.: income tax expense or benefit
• Elite Pharmaceuticals, Inc.: net property, plant and equipment
• Elite Pharmaceuticals, Inc.: share-based compensation expense
• Elite Pharmaceuticals, Inc.: operating income or loss
• Elite Pharmaceuticals, Inc.: current assets
• Elite Pharmaceuticals, Inc.: interest expense
• Elite Pharmaceuticals, Inc.: current liabilities
• Elite Pharmaceuticals, Inc.: current accounts payable
• Elite Pharmaceuticals, Inc.: net finite-lived intangible assets
• Elite Pharmaceuticals, Inc.: net current accounts receivable
• Elite Pharmaceuticals, Inc.: operating expenses
• Elite Pharmaceuticals, Inc.: net inventory
• Elite Pharmaceuticals, Inc.: gross profit
• Elite Pharmaceuticals, Inc.: cost of revenue
• Elite Pharmaceuticals, Inc.: research and development expense
• Elite Pharmaceuticals, Inc.: common shares outstanding
• Elite Pharmaceuticals, Inc.: cash including restricted cash
• Elite Pharmaceuticals, Inc.: additional paid-in capital
• Elite Pharmaceuticals, Inc.: total equity including noncontrolling interests
• Elite Pharmaceuticals, Inc.: operating lease right-of-use asset
• Elite Pharmaceuticals, Inc.: operating lease liability
• Elite Pharmaceuticals, Inc.: long-term debt
• Elite Pharmaceuticals, Inc.: gross property, plant and equipment
• Elite Pharmaceuticals, Inc.: accumulated depreciation on property, plant and equipment
• Elite Pharmaceuticals, Inc.: net intangible assets excluding goodwill
• Elite Pharmaceuticals, Inc.: other noncurrent liabilities
• Elite Pharmaceuticals, Inc.: accrued current liabilities
• Elite Pharmaceuticals, Inc.: prepaid expenses and other current assets
• Elite Pharmaceuticals, Inc.: current contract liabilities
• Elite Pharmaceuticals, Inc.: pre-tax income or loss from continuing operations
• Elite Pharmaceuticals, Inc.: net income available to common stockholders
• Elite Pharmaceuticals, Inc.: general and administrative expense
• Elite Pharmaceuticals, Inc.: depreciation expense
• Elite Pharmaceuticals, Inc.: depreciation, depletion and amortization
• Elite Pharmaceuticals, Inc.: other nonoperating income or expense
• Elite Pharmaceuticals, Inc.: nonoperating income or expense
• Elite Pharmaceuticals, Inc.: current income tax expense or benefit
• Elite Pharmaceuticals, Inc.: deferred income tax expense or benefit
• Elite Pharmaceuticals, Inc.: interest paid, net
• Elite Pharmaceuticals, Inc.: income taxes paid, net
• Elite Pharmaceuticals, Inc.: proceeds from issuing common stock
• Elite Pharmaceuticals, Inc.: change in accounts receivable
• Elite Pharmaceuticals, Inc.: change in inventories
• Elite Pharmaceuticals, Inc.: change in accounts payable

Inspect the source

Entity

Elite Pharmaceuticals, Inc. / CIK 0001053369

Captured

2026-09-20T05:17:33.154Z

SEC response SHA-256

b91e0331a01f96870ee44e841f605bd504e1bc784022b77f374cfe93dc363314

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001053369.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))